Medindia
Medindia LOGIN REGISTER
Advertisement

Diabetic Innovator Announces New Injection Aid

Friday, November 2, 2007 General News
Advertisement
SOUTHAMPTON, Mass., Nov. 1 When faced with the certaintyof daily insulin injections, innovator Chris Hillios knew he had to design adevice that would help him overcome his injection anxiety. Through hisdetermination and innovative spirit, Confidisc(TM) was developed.
Advertisement

Confidisc is an aid for injecting, by syringe or pen, insulin or likemedications. It can be used by the patient or by a caregiver. "It is trulyamazing that a simple device like Confidisc can make such a huge difference inone's life. Our testing has shown that Confidisc not only reduced painperception, it clearly reduced injection anxiety," said Chris Hillios. "Usersfocus on the disk rather than the needle." With Confidisc's help, patients'lab results are now better than ever.
Advertisement

Confidisc enables users access to a larger range of injection sites,allowing better injection rotation. It provides added stability in bothfilling the syringe and during injection. Its simple form is easy to use,convenient and cost-effective. Confidisc may be manufactured as a reusableattachment product and/or as a permanently fixed part of a hypodermic syringe.As a new hypodermic syringe, Confidisc also helps to deter illegal intravenousdrug use.

More than 18 million Americans are living with type 2 diabetes. Manysuffer from injection anxiety. Fear of injection can lead to impropertreatment and poor control. "Having first-hand knowledge of the problemsassociated with home injections, it is our belief that this product will be ofenormous benefit to the ever-growing diabetic population. Confidisc providesthe confidence I need. I will no longer inject without it," said Hillios.

Confidisc was well-received by a review of Endocrinologist, DiabeticEducators and Nurse Practitioners. They look forward to having it availablefor their patients. It is sure to be a beneficial, simple, and affordableproduct for everyone facing daily injections. "Diabetes was our primaryconcern. However, we can now see that as the self-injectable market grows, theuses for Confidisc also grow," said Hillios.

This release was issued through eReleases(TM). For more information,visit http://www.ereleases.com.PHOTOS AVAILABLE Contact: Chris Hillios P.O. Box 90 Southampton, MA 01073 Phone: 413-527-4059 http://www.confidisc.com [email protected]

SOURCE Confidisc
Sponsored Post and Backlink Submission


Latest Press Release on General News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close